News for Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO stock is a Sell.

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc.

PR NewswireNEW YORK, Jan. 2, 2025 NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeuti

Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (”œSangamo” or the ”œCompany”) (NASDAQ: [url="]SGMO[/ur

Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A. Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday.…

US stocks declined in the final session of the year but still closed out the best two-year run since 1998.

Sangamo Therapeutics faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price and future prospects.

The stock market closed the year with losses across major indices. The Nasdaq Composite, which surged 28.6% in 2024, fell by 0.9% from the previous day. The S&P

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.07%

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.26% to 42,461.52 wh...

U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.05% to 42,554.24...

Sangamo Therapeutics Inc. (SMO), a genomic medicine company, experienced a major setback as Pfizer Inc. (PFE) terminated their collaboration on a groundbreaking gene therapy for hemophilia A. The abrupt end to this partnership triggered Sangamo’s largest single-day share drop in more than 15 years. The decision came unexpectedly, with Sangamo's…

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% ...

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Sangamo Therapeutics, Inc. SGMO fell sharp...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.K.-based Aptorum Group Limited (APM) is up over 329 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.